Orthogonal ligation strategies for making well defined glycoconjugate vaccines

背景资料：用于传染病的糖缀合物疫苗代表了一个强大的新兴市场，GSK最近收购Glycovaxyn和Novartis Vaccines就是证明。使用细菌荚膜多糖作为疫苗组分具有作为预防性治疗以保护人类和动物健康的普遍适用性。然而，聚糖通常产生较差的免疫原，并且糖蛋白/糖缀合物难以以通过监管审查所需的同质形式制造。在这个项目中，我们将开发新的化学和酶的方法来制备糖缀合物疫苗，其中多个不同的多糖表位连接到蛋白载体上的特定位点。

Background: Glycoconjugate vaccines for infectious diseases represent a strong emerging market, as evidenced by the recent GSK acquisition of Glycovaxyn and Novartis Vaccines. The use of bacterial capsular polysaccharides as vaccine components has general applicability as prophylactic treatments to protect human and animal health. However, glycans generally make poor immunogens and glycoproteins/glycoconjugates are difficult to manufacture in the homogenous form necessary to pass regulatory scrutiny. In this project we will develop new chemical and enzymatic approaches for the preparation of glycoconjugate vaccines in which multiple different polysaccharide epitopes are attached to specific sites on protein carriers.